“We are pleased to announce Lundbeck has signed on as a member of Vivli,” said Rebecca Li, Vivli Executive Director. “We look forward to collaborating and providing their data to researchers in disease areas within psychiatry and neurology.”
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. Lundbeck is engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world, with products targeted in psychiatry and neurology.
“Participating in a global data sharing platform such as Vivli is just one example of how we cooperate to ensure the best possible foundation for innovation and the development of new treatment solutions,” said Lars-Peder Haahr, Lead Project Director at Lundbeck.